Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Neoleukin Therapeutics Inc (NLTX)
NASDAQ:NLTX
RESEARCH TOOLSreports
Holding NLTX?
Track your performance easily
NLTX Stock Chart & Stats
Day’s Range$3.42 - $3.59
52-Week Range― - ―
Previous Close$3.44
Volume113.19K
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next Earnings
May 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Neoleukin Therapeutics News
PremiumPre-Earnings
Is NLTX a Buy, Before Earnings?
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
NLTX FAQ
What was Neoleukin Therapeutics Inc’s price range in the past 12 months?
Currently, no data Available
What is Neoleukin Therapeutics Inc’s market cap?
Currently, no data Available
When is Neoleukin Therapeutics Inc’s upcoming earnings report date?
Neoleukin Therapeutics Inc’s upcoming earnings report date is May 08, 2024 which is 228 days ago.
How were Neoleukin Therapeutics Inc’s earnings last quarter?
Neoleukin Therapeutics Inc released its earnings results on Nov 14, 2023. The company reported -$0.408 earnings per share for the quarter, missing the consensus estimate of -$0.15 by -$0.258.
Is Neoleukin Therapeutics Inc overvalued?
According to Wall Street analysts Neoleukin Therapeutics Inc’s price is currently Overvalued.
Does Neoleukin Therapeutics Inc pay dividends?
Neoleukin Therapeutics Inc does not currently pay dividends.
What is Neoleukin Therapeutics Inc’s EPS estimate?
Neoleukin Therapeutics Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Neoleukin Therapeutics Inc have?
Currently, no data Available
What happened to Neoleukin Therapeutics Inc’s price movement after its last earnings report?
Neoleukin Therapeutics Inc reported an EPS of -$0.408 in its last earnings report, missing expectations of -$0.15. Following the earnings report the stock price went up 4.167%.
Which hedge fund is a major shareholder of Neoleukin Therapeutics Inc?
Among the largest hedge funds holding Neoleukin Therapeutics Inc’s share is Baker Bros Advisors LP. It holds Neoleukin Therapeutics Inc’s shares valued at 19M.
---
Neoleukin Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Hedge Fund Trend
Increased
By 284.9K Shares
Last Quarter.
Last Quarter.
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
64.47%
12-Months-Change
Fundamentals
Return on Equity
-37.88%
Trailing 12-Months
Asset Growth
-29.22%
Trailing 12-Months
Company Description
Neoleukin Therapeutics Inc
Neoleukin Therapeutics, Inc. is a biopharmaceutical company, which engages in the design of de novo protein therapeutics to address significant unmet medical needs in oncology, inflammation, and autoimmunity. Its lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to eliminate alpha receptor binding. The company was founded by Daniel-Adriano Silva, Carl Walkey, and Umut Ulge in December 2003 and is headquartered in Seattle, WA.
---
NLTX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---